Therapeutic Potential of Agonists and Antagonists of A1, A2a, A2b and A3 Adenosine Receptors

被引:26
|
作者
Jamwal, Sumit [1 ]
Mittal, Ashish [2 ]
Kumar, Puneet [2 ]
Alhayani, Dana M. [3 ]
Al-Aboudi, Amal [4 ]
机构
[1] Baddi Univ Emerging Sci & Technol, Sch Pharm & Emerging Sci, Baddi 173205, India
[2] MRSS Punjab Tech Univ, Dept Pharmaceut Sci, Bathinda, Punjab, India
[3] Philadelphia Univ, Fac Pharm, POB 1, Amman, Jordan
[4] Univ Jordan, Fac Sci, Amman 11942, Jordan
关键词
Adenosine; adenosine receptors; adenosine triphosphate; alzheimer's disease; cancer; asthma; epilepsy; NERVOUS-SYSTEM; PHARMACOLOGY; NEUROMODULATOR; RADIOLIGAND; ACTIVATION; TARGETS; DESIGN; KINASE; FUTURE; ROLES;
D O I
10.2174/1381612825666190716112319
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Adenosine is a naturally occurring nucleoside and an essential component of the energy production and utilization systems of the body. Adenosine is formed by the degradation of adenosine-triphosphate (ATP) during energy-consuming processes. Adenosine regulates numerous physiological processes through activation of four subtypes of G-protein coupled membrane receptors viz. A(1), A(2a), A(2b) and A(3). Its physiological importance depends on the affinity of these receptors and the extracellular concentrations reached. ATP acts as a neurotransmitter in both peripheral and central nervous systems. in the peripheral nervous system, ATP is involved in chemical transmission in sensory and autonomic ganglia, whereas in central nervous system, ATP, released from synaptic terminals, induces fast excitatory postsynaptic currents. ATP provides the energetics for all muscle movements, heart beats, nerve signals and chemical reactions inside the body. Adenosine has been traditionally considered an inhibitor of neuronal activity and a regulator of cerebral blood flow. Since adenosine is neuroprotective against excitotoxic and metabolic dysfunctions observed in neurological and ocular diseases, the search for adenosine-related drugs regulating adenosine transporters and receptors can be important for advancement of therapeutic strategies against these diseases. This review will summarize the therapeutic potential and recent SAR and pharmacology of adenosine and its receptor agonists and antagonists.
引用
收藏
页码:2892 / 2905
页数:14
相关论文
共 50 条
  • [31] Modulation of adenosine A2A rceptor function by A2B receptors
    Feoktistov, I
    Ryzhov, S
    Goldstein, A
    Matafonov, A
    Maa, T
    Zeng, DW
    Belardinelli, L
    Biaggioni, I
    [J]. HYPERTENSION, 2003, 42 (03) : 391 - 391
  • [32] Adenosine A2B receptors as therapeutic targets
    Feoktistov, I
    Wells, JN
    Biaggioni, I
    [J]. DRUG DEVELOPMENT RESEARCH, 1998, 45 (3-4) : 198 - 206
  • [33] Adenosine A1, A2a, A2b, and A3 Receptors in Hematopoiesis. 2. Expression of Receptor mRNA in Resting and Lipopolysaccharide-Activated Mouse RAW 264.7 Macrophages
    Streitova, D.
    Hofer, M.
    Hola, J.
    Vacek, A.
    Pospisil, M.
    [J]. PHYSIOLOGICAL RESEARCH, 2010, 59 (01) : 139 - 144
  • [34] Apparent activation of cardiovascular A1 adenosine receptors by A3 agonists
    Headrick, JP
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2002, 282 (02): : H793 - H794
  • [35] Evaluation of 2-benzylidene-1-tetralone derivatives as antagonists of A1 and A2A adenosine receptors
    Legoabe, Lesetja J.
    Van der Walt, Mietha M.
    Terre'Blanche, Gisella
    [J]. CHEMICAL BIOLOGY & DRUG DESIGN, 2018, 91 (01) : 234 - 244
  • [36] Roles of adenosine A2A and A3 receptors in the brain
    Lopes, LV
    Costenial, AR
    Rebola, N
    Cunha, RA
    [J]. DRUG DEVELOPMENT RESEARCH, 2002, 56 (04) : 548 - 548
  • [37] A new orally bioavailable dual adenosine A2B/A3 receptor antagonist with therapeutic potential
    Press, NJ
    Taylor, RJ
    Fullerton, JD
    Tranter, P
    McCarthy, C
    Keller, TH
    Brown, L
    Cheung, R
    Christie, J
    Haberthuer, S
    Hatto, JDI
    Keenan, M
    Mercer, MK
    Press, NE
    Sahri, H
    Tuffnell, AR
    Tweed, M
    Fozard, JR
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (12) : 3081 - 3085
  • [38] Protective roles of adenosine A1, A2A, and A3 receptors in skeletal muscle ischemia and reperfusion injury
    Zheng, Jingang
    Wang, Rubio
    Zambraski, Edward
    Wu, Dan
    Jacobson, Kenneth A.
    Liang, Bruce T.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2007, 293 (06): : H3685 - H3691
  • [39] Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury
    Gazoni, Leo M.
    Walters, Dustin M.
    Unger, Eric B.
    Linden, Joel
    Kron, Irving L.
    Laubach, Victor E.
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2010, 140 (02): : 440 - 446
  • [40] 3D-pharmacophore models for selective A2A and A2B adenosine receptor antagonists
    Wei, Jing
    Wang, Songqing
    Gao, Shaofen
    Dai, Xuedong
    Gao, Qingzhi
    [J]. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2007, 47 (02) : 613 - 625